Drug Trial Radar · NCT07383025
Mavacamten Post-marketing Surveillance in Patients With Obstructive Hypertrophic Cardiomyopathy in Japan
Last checked: Nov 20, 2026Latest source record: Feb 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
200
Planned (sponsor's estimate)
Start
May 21, 2025
Primary completion
Nov 30, 2029
Study completion Nov 30, 2029
Sponsor
- Lead sponsor
- Bristol-Myers SquibbBristol Myers Squibb (BMY)
- Sponsor type
- Industry
- First posted
- Feb 3, 2026
Design
- Study type
- Observational
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
Summary
As written by the sponsor on the registry.
The purpose of this study is to assess the real-world effectiveness and safety of mavacamten in patients with obstructive hypertrophic cardiomyopathy (HCM) receiving mavacamten in Japan
Conditions
- Obstructive Hypertrophic Cardiomyopathy (oHCM)
Interventions
MavacamtenDrug
According to the product label
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of adverse events (AEs) and/or serious AEs (SAEs)Time frame: Up to 52 weeks
- Actions taken after adverse events (AEs) and/or serious AEs (SAEs)Time frame: Up to 52 weeks
- Outcome of adverse events (AEs) and/or serious AEs (SAEs)Time frame: Up to 52 weeks
Locations
1 site in 1 country. Site status is shown where the registry gives one.
CMIC Co., Ltd
Tokyo, Japan · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.